My impression was that Lm was always better suited for prevention rather than treatment of metastatic cancer, but that these trials take longer and/or the FDA is less likely to allow them.
I invested in ADXS because I believed a cheap way to make cancer less likely to metastasize would be extremely valuable. Then the NEO-AMGN deal happened and it looked even better.
Market Data 
Markets 
AI
